Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials

Abstract

Background: A ring-shaped, contraceptive vaginal system designed to last 1 year (13 cycles) delivers an average of 0·15 mg segesterone acetate and 0·013 mg ethinylestradiol per day. We evaluated the efficacy of this contraceptive vaginal system and return to menses or pregnancy after use.

Methods: In two identically designed, multicentre, open-label, single-arm, phase 3 trials (one at 15 US academic and community sites and one at 12 US and international academic and community sites), participants followed a 21-days-in, 7-days-out segesterone acetate and ethinylestradiol contraceptive vaginal system schedule for up to 13 cycles. Participants were healthy, sexually active, non-pregnant, non-sterilised women aged 18-40 years. Women were cautioned that any removals during the 21 days of cyclic use should not exceed 2 h, and used daily paper diaries to record vaginal system use. Consistent with regulatory requirements for contraceptives, we calculated the Pearl Index for women aged 35 years and younger, excluding adjunctive contraception cycles, as the primary efficacy outcome measure. We also did intention-to-treat Kaplan-Meier life table analyses and followed up women who did not use hormonal contraceptives or desired pregnancy after study completion for 6 months for return to menses or pregnancy. The trials are registered with ClinicalTrials.gov, numbers NCT00455156 and NCT00263341.

Findings: Between Dec 19, 2006, and Oct 9, 2009, at the 15 US sites, and between Nov 1, 2006, and July 2, 2009, at the 12 US and international sites we enrolled 2278 women. Our overall efficacy analysis included 2265 participants (1130 in the US study and 1135 in the international study) and 1303 (57·5%) participants completed up to 13 cycles. The Pearl Index for the primary efficacy group was 2·98 (95% CI 2·13-4·06) per 100 woman-years, and was well within the range indicative of efficacy for a contraceptive under a woman's control. The Kaplan-Meier analysis revealed the contraceptive vaginal system was 97·5% effective, which provided further evidence of efficacy. Pregnancy occurrence was similar across cycles. All 290 follow-up participants reported return to menses or became pregnant (24 [63%] of 38 women who desired pregnancy) within 6 months.

Interpretation: The segesterone acetate and ethinylestradiol contraceptive vaginal system is an effective contraceptive for 13 consecutive cycles of use. This new product adds to the contraceptive method mix and the 1-year duration of use means that women do not need to return to the clinic or pharmacy for refills every few months.

Funding: Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health, the US Agency for International Development, and the WHO Reproductive Health Research Department.

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1

Trial profile *All contraceptive vaginal systems expired by Dec 31, 2008, and subjects were required to discontinue treatment at that time.

Figure 2

Cumulative probability of no pregnancy Cross marks indicate censoring of patients and the red shaded area indicates 95% CI.

References

1. 1. Starbird E, Norton M, Marcus R. Investing in family planning: key to achieving the sustainable development goals. Glob Health Sci Pract. 2016;4:191–210.
   2. E Starbird, M Norton, R Marcus. Investing in family planning: key to achieving the sustainable development goals. Glob Health Sci Pract. 2016; 4: 191–210
2. 1. Alkema L, Kantorova V, Menozzi C, Biddlecom A. National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planning between 1990 and 2015: a systematic and comprehensive analysis. Lancet. 2013;381:1642–1652.
   2. L Alkema, V Kantorova, C Menozzi, A Biddlecom. National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planning between 1990 and 2015: a systematic and comprehensive analysis. Lancet. 2013; 381: 1642–52
3. 1. Kavanaugh ML, Jerman J. Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014. Contraception. 2018;97:14–21.
   2. ML Kavanaugh, J Jerman. Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014. Contraception. 2018; 97: 14–21
4. 1. Mishell DR, Jr, Lumkin ME. Contraceptive effect of varying dosages of progestogen in silastic vaginal rings. Fertil Steril. 1970;21:99–103.
   2. Mishell DR Jr. ME Lumkin. Contraceptive effect of varying dosages of progestogen in silastic vaginal rings. Fertil Steril. 1970; 21: 99–103
5. 1. Kumar N, Koide SS, Tsong Y, Sundaram K. Nestorone: a progestin with a unique pharmacological profile. Steroids. 2000;65:629–636.
   2. N Kumar, SS Koide, Y Tsong, K Sundaram. Nestorone: a progestin with a unique pharmacological profile. Steroids. 2000; 65: 629–36
6. 1. Kumar N, Fagart J, Liere P. Nestorone as a novel progestin for nonoral contraception: structure-activity relationships and brain metabolism studies. Endocrinology. 2017;158:170–182.
   2. N Kumar, J Fagart, P Liere. et al. Nestorone as a novel progestin for nonoral contraception: structure-activity relationships and brain metabolism studies. Endocrinology. 2017; 158: 170–82
7. 1. Díaz S, Schiappacasse V, Pavez M. Clinical trial with nestorone subdermal contraceptive implants. Contraception. 1995;51:33–38.
   2. S Díaz, V Schiappacasse, M Pavez. et al. Clinical trial with nestorone subdermal contraceptive implants. Contraception. 1995; 51: 33–38
8. 1. Haukkamaa M, Laurikka-Routti M, Heikinheimo O, Moo-Young A. Contraception with subdermal implants releasing the progestin ST-1435: a dose-finding study. Contraception. 1992;45:49–55.
   2. M Haukkamaa, M Laurikka-Routti, O Heikinheimo, A Moo-Young. Contraception with subdermal implants releasing the progestin ST-1435: a dose-finding study. Contraception. 1992; 45: 49–55
9. 1. Gemzell-Danielsson K, Sitruk-Ware R, Creinin MD. Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation. Contraception. 2019;99:323–328.
   2. K Gemzell-Danielsson, R Sitruk-Ware, MD Creinin. et al. Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation. Contraception. 2019; 99: 323–28
10. 1. Brache V, Payán LJ, Faundes A. Current status of contraceptive vaginal rings. Contraception. 2013;87:264–272.
    2. V Brache, LJ Payán, A Faundes. Current status of contraceptive vaginal rings. Contraception. 2013; 87: 264–72
11. 1. Creasy G, Brache V, Croxatto H. User controlled long acting reversible contraception: the pharmacokinetic profile of the nestorone/ethinyl estradiol contraceptive vaginal ring (NES/EE-CVR) a 1-year cyclical re-useable vaginal ring. Eur J Contracept Reprod Health Care. 2014;19:S85.
    2. G Creasy, V Brache, H Croxatto. et al. User controlled long acting reversible contraception: the pharmacokinetic profile of the nestorone/ethinyl estradiol contraceptive vaginal ring (NES/EE-CVR) a 1-year cyclical re-useable vaginal ring. Eur J Contracept Reprod Health Care. 2014; 19: S85
12. 1. Polis CB, Hussain R, Berry A. There might be blood: a scoping review on women's responses to contraceptive-induced menstrual bleeding changes. Reprod Health. 2018;15:114.
    2. CB Polis, R Hussain, A Berry. There might be blood: a scoping review on women's responses to contraceptive-induced menstrual bleeding changes. Reprod Health. 2018; 15: 114
13. 1. Yang G, De Staercke C, Hooper WC. The effects of obesity on venous thromboembolism: a review. Open J Prev Med. 2012;2:499–509.
    2. G Yang. De Staercke C. WC Hooper. The effects of obesity on venous thromboembolism: a review. Open J Prev Med. 2012; 2: 499–509
14. 1. Brache V, Massai R, Mishell DR. Ovarian function during use of Nestorone(R) subdermal implants. Contraception. 2000;61:199–204.
    2. V Brache, R Massai, DR Mishell. et al. Ovarian function during use of Nestorone(R) subdermal implants. Contraception. 2000; 61: 199–204
15. 1. Portman DJ, Kaunitz AM, Howard B, Weiss H, Hsieh J, Ricciotti N. Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive. Contraception. 2014;89:299–306.
    2. DJ Portman, AM Kaunitz, B Howard, H Weiss, J Hsieh, N Ricciotti. Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive. Contraception. 2014; 89: 299–306
16. 1. Lybrel (90 mcg levonorgestrel and 20 mcg ethinyl estradiol) tablets Prescribing Information. Wyeth Pharmaceuticals; Philadelphia: 2010.
    2. Lybrel (90 mcg levonorgestrel and 20 mcg ethinyl estradiol) tablets. Prescribing Information. Philadelphia: Wyeth Pharmaceuticals, 2010.
17. 1. Kroll R, Reape KZ, Margolis M. The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol. Contraception. 2010;81:41–48.
    2. R Kroll, KZ Reape, M Margolis. The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol. Contraception. 2010; 81: 41–48
18. 1. Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets ethinyl estradiol tablets and ferrous fumarate tablets) Prescribing Information. Warner Chilcott; Rockaway: 2010.
    2. Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets). Prescribing Information. Rockaway: Warner Chilcott, 2010.
19. 1. Chowdhury V, Joshi UM, Gopalkrishna K, Betrabet S, Mehta S, Saxena BN. ‘Escape’ ovulation in women due to the missing of low dose combination oral contraceptive pills. Contraception. 1980;22:241–247.
    2. V Chowdhury, UM Joshi, K Gopalkrishna, S Betrabet, S Mehta, BN Saxena. ‘Escape’ ovulation in women due to the missing of low dose combination oral contraceptive pills. Contraception. 1980; 22: 241–47
20. 1. Winner B, Peipert JF, Zhao Q. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366:1998–2007.
    2. B Winner, JF Peipert, Q Zhao. et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012; 366: 1998–2007
21. 1. Kazerooni R, Blake A, Thai J. Predictors of pregnancy in female veterans receiving a hormonal contraceptive pill, patch, or ring. Ann Pharmacother. 2015;49:1284–1290.
    2. R Kazerooni, A Blake, J Thai. Predictors of pregnancy in female veterans receiving a hormonal contraceptive pill, patch, or ring. Ann Pharmacother. 2015; 49: 1284–90
22. 1. Lobo Abascal P, Luzar-Stiffler V, Giljanovic S, Howard B, Weiss H, Trussell J. Differences in reporting Pearl Indices in the United States and Europe: focus on a 91-day extended regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation. Eur J Contracept Reprod Health Care. 2016;21:88–91.
    2. Lobo Abascal P. V Luzar-Stiffler, S Giljanovic, B Howard, H Weiss, J Trussell. Differences in reporting Pearl Indices in the United States and Europe: focus on a 91-day extended regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation. Eur J Contracept Reprod Health Care. 2016; 21: 88–91
23. 1. Barnett C, Hagemann C, Dinger J, Do Minh T, Heinemann K. Fertility and combined oral contraceptives—unintended pregnancies and planned pregnancies following oral contraceptive use—results from the INAS-SCORE study. Eur J Contracept Reprod Health Care. 2017;22:17–23.
    2. C Barnett, C Hagemann, J Dinger. Do Minh T. K Heinemann. Fertility and combined oral contraceptives—unintended pregnancies and planned pregnancies following oral contraceptive use—results from the INAS-SCORE study. Eur J Contracept Reprod Health Care. 2017; 22: 17–23
24. 1. Westhoff CL, Torgal AT, Mayeda ER, Shimoni N, Stanczyk FZ, Pike MC. Predictors of noncompliance in an oral contraceptive clinical trial. Contraception. 2012;85:465–469.
    2. CL Westhoff, AT Torgal, ER Mayeda, N Shimoni, FZ Stanczyk, MC Pike. Predictors of noncompliance in an oral contraceptive clinical trial. Contraception. 2012; 85: 465–69
25. 1. Rocca CH, Harper CC. Do racial and ethnic differences in contraceptive attitudes and knowledge explain disparities in method use? Perspect Sex Reprod Health. 2012;44:150–158.
    2. CH Rocca, CC Harper. Do racial and ethnic differences in contraceptive attitudes and knowledge explain disparities in method use?. Perspect Sex Reprod Health. 2012; 44: 150–58
26. 1. Gerlinger C, Trussell J, Mellinger U. Different Pearl Indices in studies of hormonal contraceptives in the United States: impact of study population. Contraception. 2014;90:142–146.
    2. C Gerlinger, J Trussell, U Mellinger. et al. Different Pearl Indices in studies of hormonal contraceptives in the United States: impact of study population. Contraception. 2014; 90: 142–46
27. 1. Trussell J, Portman D. The creeping Pearl: why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills? Contraception. 2013;88:604–610.
    2. J Trussell, D Portman. The creeping Pearl: why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills?. Contraception. 2013; 88: 604–10
28. 1. Kemet S, Lundsberg LS, Gariepy AM. Race and ethnicity may not be associated with risk of unintended pregnancy. Contraception. 2018;97:313–318.
    2. S Kemet, LS Lundsberg, AM Gariepy. Race and ethnicity may not be associated with risk of unintended pregnancy. Contraception. 2018; 97: 313–18
29. 1. Stifani BM, Plagianos M, Vieira CS, Merkatz RB. Factors associated with nonadherence to instructions for using the Nestorone/ethinyl estradiol contraceptive vaginal ring. Contraception. 2018;97:415–421.
    2. BM Stifani, M Plagianos, CS Vieira, RB Merkatz. Factors associated with nonadherence to instructions for using the Nestorone/ethinyl estradiol contraceptive vaginal ring. Contraception. 2018; 97: 415–21
30. 1. Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect. 1999;31:64–72.
    2. J Trussell, B Vaughan. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect. 1999; 31: 64–72